Opinion|Videos|November 20, 2026

Comparing Toxicity Profiles and Treatment Considerations in Relapsed/Refractory Multiple Myeloma

Dr. Joshua Richter and Dr. Surbhi Sidana compare the safety profiles and practical considerations of BCMA-directed CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) in relapsed/refractory multiple myeloma.

Dr. Joshua Richter and Dr. Surbhi Sidana compare the safety profiles and practical considerations of BCMA-directed CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) in relapsed/refractory multiple myeloma. Dr. Sidana discusses the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) with T-cell-engaging therapies, as well as the infection risks associated with continuous bispecific antibody treatment. She highlights the role of immunoglobulin replacement with intravenous immunoglobulin (IVIG) as an infection-prevention strategy. In contrast, ADC-associated toxicities are primarily ocular, including corneal changes, dryness, and blurred vision, which may improve after treatment interruption. The experts also review the distinct taste, skin, and nail-related adverse effects associated with talquetamab, a GPRC5D-directed bispecific antibody, and discuss less common but serious delayed neurotoxicities and immune effector cell-associated enterocolitis with CAR T-cell therapy. Dr. Richter emphasizes the importance of individualized risk-benefit discussions, including consideration of potential secondary malignancies and patient preferences when selecting treatment.


Related to this article